Vericel Corp (VCEL) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) reached $0.10, significantly surpassing Wall Street's consensus estimate of $-0.01. Revenue matched expectations at $0.1 billion.
This update provides insight into Vericel's recent operational performance and financial health. The strong EPS suggests that the company is navigating its market effectively, given its focus on advanced cellular therapies for sports medicine and severe burn care.
Vericel markets three primary products in the United States, including MACI, an autologous-cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for severe burns. The firm also holds a license for NexoBrid, which aids in the treatment of thermal burns.
The company will host its earnings conference call at 8:00 AM ET to discuss these results and provide further commentary on business performance. Investors are encouraged to review the full earnings release for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Vericel holds a market capitalization of $1,955.33 million and a trailing P/E ratio of 275.13. Looking ahead, the company anticipates its next earnings report on July 28, 2026, with EPS estimated at $0.0551 and revenue expected to remain at $0.1 billion.